Skip to main content

Dean Farmer, PhD

Member

[email protected]

+1.617.348.3048

Share:

Dean is a leading patent strategist in the life sciences sector who works with biotechnology and pharmaceutical companies at all stages of development. His clients range from start-ups, to mid-size pharmas with NCEs entering clinical trials, to large companies with vast patent portfolios.

Dean’s years working in the industry and two decades in patent law position him as a strategic partner for his clients. He helps them understand the risks and opportunities associated with various approaches to protecting their innovations and helps them develop and implement strategies centered on their business goals. Dean handles patent procurement, portfolio management, IP due diligence, and opinions including freedom-to-operate, validity, and patentability assessments in the areas of chemistry, pharmaceuticals, and biotechnology. With deep experience in business, chemistry, and IP law, he understands the business risks and complexities facing companies in the biopharmaceutical sector in ways that others lacking his unique combination of perspectives cannot — and leverages his exceptional insight to help clients navigate IP risks and shifting industry challenges.

He is recognized as a leading patent lawyer by Legal 500 and IAM Patent 1000 and has been a recipient of the Healthcare & Life Sciences – Massachusetts Client Choice Award.

Dean’s work as a scientist focused on synthetic organic chemistry, drug/nucleic acid interactions, drug/protein interactions, and complex target protein interactions. He earned his PhD in Organic Chemistry at Brown University, where he worked in the lab of Bill Suggs and was awarded the AT&T–Brown Faculty Scientific Achievement Award. He then studied with Stuart Schreiber at Harvard University as an American Cancer Society postdoctoral fellow and recipient of the NIH postdoctoral fellowship.

Dean’s thesis work was directed to the total synthesis (14 steps) of dimeric-anthramycin analogs and the study of their DNA binding specificity. Representative of his work in the Schreiber laboratories is the publication in 1991 that small molecules FK506 and cyclosporin inhibit the activity of the phosphatase calcineurin by forming the ternary complexes FKBP12-FK506-calcineurin and cyclophilin-cyclosporin-calcineurin (Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL, “Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes,” Cell 66 (4): 807–15, Schreiber’s most cited work to date.

Select Research Publications

  • J.D. Farmer, Jr., S.M. Rudnicki, and J.W. Suggs, "Synthesis and DNA Crosslinking Ability of a Dimeric Anthramycin Analog," Tetrahedron Letters, 29, 5105, (1988)
  • J. Dean Farmer, Jr., G. R. Gustafson, A. Conti and M. B. Zimmt, and J.W. Suggs, "DNA Binding Properties of a New Class of Linked Anthramycin Analogs," Nucleic Acids Res., 19, 899 (1991)
  • Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL, "Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes," Cell 66 (4): 807–15 (1991)
  • J. Dean Farmer Jr., Gary R. Gustafson, and J. William Suggs, "Reversible DNA Crosslinking by Dimeric Analogs Anthramycin," Sixth Conversation in Biomolecular Stereodynamics; R.H. Sarma, ed., Institute of Biomolecular Stereodynamics Press, Albany NY, A49 (1989)
  • J.Dean Farmer, Jr. and J. William Suggs, "Small Molecule - Large Molecule Interactions: Increasing the Selectivity of Certain Restriction Enzymes," Sixth Conversation in Biomolecular Stereodynamics; R.H. Sarma, ed., Institute of Biomolecular Stereodynamics Press, Albany NY, A49, p. 95 (1989)

viewpoints

A “picture” claim refers to a patent claim precisely tailored to track a particular product’s important advantages and features. When drafting a patent application, one should describe various embodiments of the invention and include both picture claims, tailored to those embodiments, and broader claims, to encompass groups of embodiments.

Read more

Patent offices may reject a patent application with claims reciting using a composition to treat a disease, based on the requirement that the claimed treatment is not fully supported by the application.

Read more

An invention is not patentable if it was described in, or obvious in view of, an earlier printed publication. See 35 U.S.C. 102(a)(1). This blog post addresses how to overcome an anticipation or obviousness rejection where an inventor is the author or otherwise the source of subject matter in the publication cited as prior art

Read more
Read less

News & Press

Press Release Thumbnail

Our Intellectual Property Practice earned national recognition in the 2024 edition of IAM Patent 1000 – The World’s Leading Patent Practitioners. The guide recognized Mintz with four firm-wide rankings and 14 individual attorney recommendations, including a gold ranking for Intellectual Property Chair Michael Renaud.

Press Release Thumbnail

Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.

Press Release Thumbnail

BOSTON, MA – In the 2023 edition of 'IP Stars,' published by Managing Intellectual Property (Managing IP), Mintz achieved recognition in two nationwide categories and received acknowledgment for the exceptional performance of nine of its attorneys.

Press Release Thumbnail

BOSTON– Mintz’s award-winning Intellectual Property (IP) Practice again earned national recognition in the 2023 edition of IAM Patent 1000 – The World’s Leading Patent Practitioners. The guide recognized Mintz with three firm-wide rankings and 10 attorneys received a total of 11 individual recommendations.

Press Release Thumbnail

We're thrilled to announce the addition of 17 new Members to Mintz. Along with seven attorneys recently elevated to membership in the firm, we’ve welcomed ten lateral Members in 2022. They add depth to our experience and capabilities in life sciences, health care, financial services, private equity, sports & entertainment, technology, and other sectors.

Press Release Thumbnail

A team of two new Members and an Of Counsel with deep patenting capabilities and decades of experience supporting biotech and pharmaceutical clients enhances our already robust Life Sciences IP prosecution and strategy practice.

Read less

Events & Speaking

Panelist
Jul
2
2024
Conference Reference Image
Read less

Dean is a leading patent strategist in the life sciences sector who works with biotechnology and pharmaceutical companies at all stages of development. His clients range from start-ups, to mid-size pharmas with NCEs entering clinical trials, to large companies with vast patent portfolios.

Recognition & Awards

  • Identified in the IAM Patent 1000, a listing of the “World’s Leading Patent Practitioners” 

  • Legal 500: Recognized as a leading patent attorney

  • Massachusetts Client Choice Award: Healthcare & Life Sciences 

  • Best Lawyers in America: Patent Law (2024)

  • Managing Intellectual Property: Patent Star (2024)

Read less

Dean is a leading patent strategist in the life sciences sector who works with biotechnology and pharmaceutical companies at all stages of development. His clients range from start-ups, to mid-size pharmas with NCEs entering clinical trials, to large companies with vast patent portfolios.

Involvement

  • Member, American Bar Association
  • Member, American Intellectual Property Association
  • Member, Boston Intellectual Property Law Association
  • Member, American Chemical Society
Read less